For Q4 2024, the Harding Loevner International Developed Markets Equity composite fell 8.4% (gross) behind the 7.4% decline ...
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Harding Loevner International Equity ADR composite fell 7.9%, gross, behind the 7.5% decline of the MSCI ACWI ex US Index.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback